366 related articles for article (PubMed ID: 21439330)
1. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
[TBL] [Abstract][Full Text] [Related]
4. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
6. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
[TBL] [Abstract][Full Text] [Related]
7. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
8. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
10. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Boeri E; Spagnuolo V; Cossarini F; Castagna A; Lazzarin A; Clementi M
J Infect Dis; 2011 Dec; 204(11):1811-5. PubMed ID: 21984737
[TBL] [Abstract][Full Text] [Related]
12. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
13. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
14. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
15. Evolution of raltegravir resistance during therapy.
Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
[TBL] [Abstract][Full Text] [Related]
16. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
[TBL] [Abstract][Full Text] [Related]
17. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
[TBL] [Abstract][Full Text] [Related]
18. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
Cavalcanti Jde S; Ferreira JL; Guimarães PM; Vidal JE; Brigido LF
J Antimicrob Chemother; 2015 Mar; 70(3):926-9. PubMed ID: 25386009
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
20. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
